Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01957748
Other study ID # CCTG 594
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 8, 2013
Est. completion date November 24, 2020

Study information

Verified date December 2021
Source University of California, San Diego
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

CCTG 594 is a controlled, unblinded, two-arm, randomized (1:1) clinical trial to evaluate the effectiveness of a clinic-based HIV ALERT specialist on improving endpoints of retention in care and maintenance of ART as compared to the current standard of care (SoC) in HIV primary care clinics.


Description:

Design: CCTG 594 is a controlled, unblinded, two-arm, randomized (1:1) clinical trial to evaluate the effectiveness of a clinic-based HIV ALERT specialist on improving endpoints of retention in care and maintenance of ART as compared to the current standard of care (SoC) in HIV primary care clinics. Duration: Each subject will receive follow-up of at least 48 weeks. Sample Size: A total of 300 subjects will be randomized, 150 per arm. Study Population: Eligible subjects will include 1) newly diagnosed HIV-infected individuals entering primary HIV care at one of the CCTG clinics, or 2) previously diagnosed HIV-infected individuals who are "out of care" defined as having no visit with a prescribing HIV provider in the last 180 days and not on a stable ARV regimen. Stratification: Subjects will be stratified based on study site and if they are newly diagnosed or returning to care.


Recruitment information / eligibility

Status Completed
Enrollment 117
Est. completion date November 24, 2020
Est. primary completion date December 15, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - HIV-1 infection, as documented by any licensed screening antibody test, such as ELISA, and confirmed by a second antibody test, such as Western blot, or detectable plasma HIV-1 RNA at any time prior to study entry. If an ELISA or Western blot is not available, HIV infection may be documented by two HIV RNA values =2000 copies/mL, drawn at least 24 hours apart. The RNA assays must have been run at a CLIA-approved laboratory or equivalent. - 18 years of age or older. - Able to give written informed consent. - New patient to the clinic (defined as someone who has never engaged in HIV care) or a patient returning to care (defined as a patient previously seen at least once by a prescribing HIV provider who has not seen a prescribing HIV provider in the last 180 days and is not on a stable ARV regimen). - English or Spanish Speaking. - Registered to receive HIV primary care services at one of the identified CCTG-affiliated clinic, i.e. the Owen Clinic at UC San Diego Health System, Harbor-UCLA Medical Center clinic or Rand Schrader clinic at USC. Exclusion Criteria: - Unstable neurologic, psychiatric, or physical condition which, in the opinion of the investigator, would limit participation with study procedures for the duration of the study. - A level of drug or alcohol use that, in the opinion of the investigator, would preclude safe participation in the study. - Resident of nursing home or skilled facility. - Pregnant or breastfeeding. - Patient's first primary care visit (for new patients) or return to care visit (for patients returning to care) occurred > 60 days ago.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
SoC + ALERT Intervention
Enhanced retention efforts and education modules will be implemented by the ALERT Specialist to ensure retention to care.

Locations

Country Name City State
United States University Southern California Los Angeles California
United States University of California, San Diego San Diego California
United States Harbor-UCLA Medical Center Torrance California

Sponsors (5)

Lead Sponsor Collaborator
University of California, San Diego California HIV/AIDS Research Program, City of Long Beach Department of Health and Human Services, University of California, Los Angeles, University of Southern California

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Descriptive analyses Descriptive secondary analyses comparing the two randomized groups will include:
Baseline and follow-up scores on HIV and health literacy assessments, disclosure rates, adherence, and measures of self-efficacy
Number of primary care visits per year
HIV RNA < 50 and <200 copies/mL at years 1 and 2
CD4 cell counts and changes from baseline in CD4 at years 1 through 2
Scores on Beck Depression Index
Substance use
HIV high-risk transmission behaviors
Time to AIDS diagnosis or death
Baseline to two years
Other Return to Care after Primary Endpoint Proportions of subjects that meet the primary endpoint but subsequently return to care will be compared between the randomized groups. The times between last visit and return visit will also be compared between the randomized groups. Baseline to 2 years
Primary Time to lost to follow up The CCTG 594 primary outcome is "time to lost to follow up." Lost to follow up is defined as "no visit with a prescribing HIV provider in the last 180 days. All randomized subjects will be followed for a minimum of 48 weeks. Subjects that do not meet the primary endpoint by the time the study ends will be censored. Baseline to Week 48
Secondary Time to initiation of ART The CCTG 594 secondary outcome is "time to initiation of ART." All randomized subjects will be followed for a minimum of 48 weeks. Subjects that do not initiate ART will be censored at their last visit date. Baseline to Week 48
See also
  Status Clinical Trial Phase
Completed NCT00639145 - Elizabeth Glaser Pediatric AIDS Foundation Maternal Events and Pregnancy Outcomes (MEP Project)A Multi-site Protocol
Completed NCT01152684 - Complementary & Alternative Medicine Use in HIV+ Latinos in the US-Mexico Border
Completed NCT01818258 - IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children Phase 4
Withdrawn NCT03660722 - Bone, Inflammation, Gut and Renal Biomarkers in Antiretroviral Naïve HIV-1 Positive Subjects N/A
Completed NCT01793467 - Transplantation and the Use of Raltegravir in HIV-Infected Patients N/A
Completed NCT02938377 - Alcohol Research Consortium in HIV-Intervention Research Arm Phase 4
Completed NCT01898754 - Oligonucleotide Ligation Assay (OLA) Resistance Study N/A
Active, not recruiting NCT01365065 - Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy Phase 2
Completed NCT00106795 - Relationship Between Fatigue and Mitochondrial Damage in Patients With HIV/AIDS N/A
Not yet recruiting NCT02404233 - Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects Phase 4
Completed NCT01154543 - Safety and Efficacy of Famciclovir in HIV1 Positive Adults With Recurrent Genital Herpes N/A
Completed NCT01154556 - RETRIeVE: ReversE TranscRiptase Inhibitor hiV Practice N/A
Completed NCT00857350 - The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment N/A
Recruiting NCT01875588 - Thinking and Memory Problems in People With HIV
Completed NCT01941121 - CCTG 593: Testing and Linkage to Care N/A
Terminated NCT01904201 - Evaluation of a Blood Test to Measure Immune Function in HIV Positive People Compared With HIV Negative People N/A
Enrolling by invitation NCT00941889 - The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata N/A
Completed NCT03531749 - Antioxidant in Patients HIV+ Supplemented With Microencapsulated of Red Pomegranate N/A
Completed NCT02935296 - Integrated Treatment and Prevention for People Who Inject Drugs Phase 3
Completed NCT01536899 - Medical Marijuana Use in HIV+ Patients Prospective Cohort Study